Triumph
Over Cancer
Begins Here
TriNetra™-Triumph is a Multi-Cancer Early Detection (MCED) test to screen for 50 types of cancers to increase the chance of detecting cancer early.
Triumph
What
A prescription blood test that indicates
likely presence of cancers based on the existence of
Circulating Tumor Cells (CTCs).
For Whom
Asymptomatic individuals with a higher risk of developing cancer, typically recommended for individuals above the age of 40 years and who do not have prior history of cancer.
How
When Circulating Tumor Cells are detected, the results can indicate the possible location of the tumor in the body, allowing your healthcare provider to advise your next steps.
Why
Screening tests are advised for only 5 cancers8. Where available, it may be an inconvenient procedure that necessitates a visit to an advanced healthcare facility. TriNetra™- Triumph indicates likely presence of cancers through a simple blood draw.
What
A prescription blood test that indicates likely presence of cancers based on the existence of Circulating Tumor Cells (CTCs).
For Whom
Asymptomatic individuals with a higher risk of developing cancer, typically recommended for individuals above the age of 40 years and who do not have prior history of cancer.
How
When Circulating Tumor Cells are detected, the results can indicate the possible location of the tumor in the body, allowing your healthcare provider to advise your next steps.
Why
Screening tests are advised for only 5 cancers8. Where available, it may be an inconvenient procedure that necessitates a visit to an advanced healthcare facility. TriNetra™- Triumph indicates likely presence of cancers through a simple blood draw.
Revolutionary Technology
Our ground-breaking, internationally acclaimed research in 2020, where we reported the discovery of a new ‘Cancer Hallmark’ i.e., Circulating Ensembles of Tumor Associated Cells, which are common in the blood of patients with cancer and are undetectable in completely healthy individuals1,2,7. Circulating Tumor Cells (CTCs) are the essential component of these clusters.
Advantages
- Non-invasive, safe, convenient, and patient-friendly.
- No need for hospitalization/visit to an advanced healthcare facility.
- No inconveniences and no procedural risks.
- No exposure to radiation.
- Can improve the early detection of cancers for which standard screening is available.
- Can help early detection of cancers for which no screening is offered8.
Effect of Our Proprietary CEM on Benign Cells, PBMCs and Cancer Cells
(CEM = CTC Enrichment Medium, PBMCs = Peripheral Blood Mononuclear Cells)
Our novel process for functional enrichment of CTCs is based on apoptosis reluctance, a hallmark of cancer cells. The process selectively eliminates all non-malignant cells (which have an intact apoptosis mechanism) while malignant cells (which evade apoptosis) survive. Circulating tumor cells and their clusters are ubiquitous in the blood of individuals with cancer and are uncommon in patients with benign conditions or otherwise healthy individuals.
Essential Safety Information
The TriNetra™-Triumph test is advised for use in adults with a higher risk of developing cancer, typically recommended for individuals above the age of 40 years and who do not have prior history of cancer. The TriNetra™-Triumph test should be used in addition to other cancer screening procedures advised by a healthcare professional. The objective of using TriNetra™-Triumph is to identify cancer footprints i.e. CTCs and identify the probable organ / location that may be affected. TriNetra™-Triumph should not be used by pregnant women. TriNetra™-Triumph should never be used as the sole means of diagnosis and the results must always be corroborated by Standard of Care methodologies undertaken through a duly qualified and authorized medical professional.
A healthcare professional should interpret the results in light of the patient’s medical history, physical symptoms, and clinical indicators. A “No Circulating Tumor Cells Detected” test result merely signifies a reduced risk of presence of cancer but it however does not definitively exclude the possibility of cancer. A “Circulating Tumor Cells Detected” test result must necessarily be confirmed by independent diagnostic evaluation using medically accepted Standard of Care techniques (like imaging, for example) and a positive result does not confirm the existence of cancer.
If additional testing does not confirm the presence of cancer, it may indicate that cancer is not currently present (the TriNetra™-Triumph test is ‘false-positive’), and ‘watchful waiting’ is advised subject to the opinion of the individual’s prescribing physician. It is clarified that owing to the diverse biological behavior of cancer and/or the technical limitations of the performance of the test, it is possible for the test findings to be both false-positive (a biological footprint suggestive of cancer is found when cancer is not present) and false-negative (a biological footprint suggestive of cancer is not identified when cancer is present). Prescription Required.
Information from the laboratory about the test
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) has certified Datar Cancer Genetics clinical laboratory in Guildford, UK, and the College of American Pathologists (CAP) has granted it accreditation. The TriNetra™-Triumph test was developed by Datar Cancer Genetics, and the laboratory has determined the performance parameters of the test. The Food and Drug Administration (US-FDA) has neither approved, endorsed, nor cleared the TriNetra™-Triumph test. High-complexity testing is regulated under the CLIA regime in the Company’s clinical laboratory. The TriNetra™-Triumph test is designed to be used in a clinical setting only.
1. Akolkar et al, Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer, Int J Oncol 2019, https://doi.org/10.1002/ijc.32815.
2. Ranade et al, Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk, Cancer Prev Res (Phila) (2021) 14 (1): 11–16, https://doi.org/10.1158/1940-6207.CAPR-20-0322
3. Gaya et al., Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol 2021. https://doi.org/10.1002/cncy.22366
4. Limaye et al. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. Cancer Med. 2023; 12: 9116- 9127. doi:10.1002/cam4.5649
5. Crook et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers 2022, 14, 3341. https://doi.org/10.3390/cancers14143341.
6. https://www.cancer.gov/about-cancer/screening/screening-tests
7. Lawrence, R., et al. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol 20, 487–500 (2023). https://doi.org/10.1038/s41571-023-00781-y.
8. US Preventive Services Task Force. Recommendations Cancer. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results.
Contact Us
500 EastRidge, Perimeter Park, Morrisville, Raleigh, North Carolina 27560,
United States of America.
4 Frederick Sanger Road, The Surrey Research Park, Guildford, Surrey, GU2 7YD,
United Kingdom.